CNM Publications 2009 to Present

Found 95 results
Author Title Type [ Year(Asc)]
2009
Park J-H, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ.  2009.  Biodegradable luminescent porous silicon nanoparticles for in vivo applications.. Nat Mater. 8(4):331-6.
Fogal V, Sugahara KN, Ruoslahti E, Christian S.  2009.  Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature.. Angiogenesis. 12(1):91-100.
Teesalu T, Sugahara KN, Kotamraju VRamana, Ruoslahti E.  2009.  C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.. Proc Natl Acad Sci U S A. 106(38):16157-62.
Simberg D, Zhang W-M, Merkulov S, McCrae K, Park J-H, Sailor MJ, Ruoslahti E.  2009.  Contact activation of kallikrein-kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo.. J Control Release. 140(3):301-5.
Wang H, Zhang W, Tang R, Hebbel RP, M Kowalska A, Zhang C, Marth JD, Fukuda M, Zhu C, Huo Y.  2009.  Core2 1-6-N-glucosaminyltransferase-I deficiency protects injured arteries from neointima formation in ApoE-deficient mice.. Arterioscler Thromb Vasc Biol. 29(7):1053-9.
Wang H, Tang R, Zhang W, Amirikian K, Geng Z, Geng J, Hebbel RP, Xia L, Marth JD, Fukuda M et al..  2009.  Core2 1-6-N-glucosaminyltransferase-I is crucial for the formation of atherosclerotic lesions in apolipoprotein E-deficient mice.. Arterioscler Thromb Vasc Biol. 29(2):180-7.
Simberg D, Park J-H, Karmali PP, Zhang W-M, Merkulov S, McCrae K, Bhatia SN, Sailor M, Ruoslahti E.  2009.  Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance.. Biomaterials. 30(23-24):3926-33.
Rumjantseva V, Grewal PK, Wandall HH, Josefsson EC, Sørensen ALouise, Larson G, Marth JD, Hartwig JH, Hoffmeister KM.  2009.  Dual roles for hepatic lectin receptors in the clearance of chilled platelets.. Nat Med. 15(11):1273-80.
Kastantin M, Ananthanarayanan B, Karmali P, Ruoslahti E, Tirrell M.  2009.  Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles.. Langmuir. 25(13):7279-86.
Stone EL, Ismail MNazri, Lee SHo, Luu Y, Ramirez K, Haslam SM, Ho SB, Dell A, Fukuda M, Marth JD.  2009.  Glycosyltransferase function in core 2-type protein O glycosylation.. Mol Cell Biol. 29(13):3770-82.
Zanuy D, Flores-Ortega A, Jiménez AI, M Calaza I, Cativiela C, Nussinov R, Ruoslahti E, Alemán C.  2009.  In silico molecular engineering for a targeted replacement in a tumor-homing peptide.. J Phys Chem B. 113(22):7879-89.
Montpetit ML, Stocker PJ, Schwetz TA, Harper JM, Norring SA, Schaffer L, North SJ, Jang-Lee J, Gilmartin T, Head SR et al..  2009.  Regulated and aberrant glycosylation modulate cardiac electrical signaling.. Proc Natl Acad Sci U S A. 106(38):16517-22.
Zhang Y, Yang M, Park J-H, Singelyn J, Ma H, Sailor MJ, Ruoslahti E, Ozkan M, Ozkan C.  2009.  A surface-charge study on cellular-uptake behavior of F3-peptide-conjugated iron oxide nanoparticles.. Small. 5(17):1990-6.
Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Marth JD, Bertozzi CR, Hart GW, Etzler ME.  2009.  Symbol nomenclature for glycan representation.. Proteomics. 9(24):5398-9.
Park J-H, von Maltzahn G, Zhang L, Derfus AM, Simberg D, Harris TJ, Ruoslahti E, Bhatia SN, Sailor MJ.  2009.  Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting.. Small. 5(6):694-700.
Peters D, Kastantin M, Kotamraju VRamana, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E.  2009.  Targeting atherosclerosis by using modular, multifunctional micelles.. Proc Natl Acad Sci U S A. 106(24):9815-9.
Karmali PPrakash, Kotamraju VRamana, Kastantin M, Black M, Missirlis D, Tirrell M, Ruoslahti E.  2009.  Targeting of albumin-embedded paclitaxel nanoparticles to tumors.. Nanomedicine. 5(1):73-82.
Sugahara KN, Teesalu T, Karmali PPrakash, Kotamraju VRamana, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E.  2009.  Tissue-penetrating delivery of compounds and nanoparticles into tumors.. Cancer Cell. 16(6):510-20.

Pages